Al-Sukhni Eisar, Attwood Kristopher, Mattson David M, Gabriel Emmanuel, Nurkin Steven J
Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Ann Surg Oncol. 2016 Apr;23(4):1177-86. doi: 10.1245/s10434-015-5017-y. Epub 2015 Dec 14.
Some patients with rectal cancer who receive neoadjuvant chemoradiotherapy (nCRT) achieve a pathologic complete response (pCR) and may be eligible for less radical surgery or non-operative management. The aim of this study was to identify variables that predict pCR after nCRT for rectal cancer and to examine the impact of pCR on postoperative complications.
A retrospective review was performed of the NCDB from 2006 to 2011. Patients with rectal cancer who received nCRT followed by radical resection were included in this study. Multivariable analysis of the association between clinicopathologic characteristics and pCR was performed, and propensity-adjusted analysis was used to identify differences in postoperative morbidity between pCR and non-pCR patients.
A total of 23,747 patients were included in the study. Factors associated with pCR included lower tumor grade, lower clinical T and N stage, higher radiation dose, and delaying surgery by more than 6-8 weeks after the end of radiation, while lack of health insurance was linked with a lower likelihood of pCR. Complete response was not associated with an increased risk of major postoperative complications.
Several clinical, pathologic, and treatment variables can help to predict which patients are most likely to have pCR after nCRT for rectal cancer. Awareness of these variables can be valuable in counseling patients regarding prognosis and treatment options.
一些接受新辅助放化疗(nCRT)的直肠癌患者可实现病理完全缓解(pCR),可能适合行创伤较小的手术或非手术治疗。本研究旨在确定预测直肠癌新辅助放化疗后pCR的变量,并探讨pCR对术后并发症的影响。
对2006年至2011年的国家癌症数据库(NCDB)进行回顾性分析。本研究纳入接受新辅助放化疗后行根治性切除术的直肠癌患者。对临床病理特征与pCR之间的关联进行多变量分析,并采用倾向调整分析来确定pCR患者与非pCR患者术后发病率的差异。
本研究共纳入23747例患者。与pCR相关的因素包括肿瘤分级较低、临床T和N分期较低、放疗剂量较高以及放疗结束后手术延迟超过6 - 8周,而缺乏医疗保险与pCR可能性较低相关。完全缓解与术后主要并发症风险增加无关。
一些临床、病理和治疗变量有助于预测哪些患者在直肠癌新辅助放化疗后最有可能出现pCR。了解这些变量对于向患者提供预后和治疗选择方面的咨询很有价值。